Novartis AG
NVSNYSEHealthcare● Active
$149.16
+$0.76(+0.51%)
Market Cap$284.6B
P/E Ratio—
52W High$170.46
52W Low$112.34
Novartis AG（NVS）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NVS · 截至 2026-06-08
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $14.06B | $11.94B | $8.57B | $6.05B | $22.91B |
| Depreciation & Amort. | $5.35B | $6.07B | $8.28B | $6.71B | $5.60B |
| Stock-Based Comp. | $0.00B | $1.04B | $0.86B | $0.79B | $0.70B |
| Change in Working Capital | ($3.08B) | ($0.71B) | ($0.37B) | ($0.80B) | ($0.07B) |
| Net Cash from Operations | $19.24B | $17.62B | $14.46B | $14.24B | $15.07B |
| Investing Activities | |||||
| Capital Expenditure | ($1.56B) | ($3.81B) | ($2.75B) | ($2.24B) | ($2.56B) |
| Purchases of Investments | ($0.30B) | ($3.65B) | ($0.75B) | ($34.81B) | ($16.59B) |
| Sales of Investments | $2.19B | $3.70B | $11.60B | $39.49B | $2.74B |
| Net Cash from Investing | ($4.90B) | ($7.51B) | $5.60B | $1.47B | $4.21B |
| Financing Activities | |||||
| Common Stock Repurchased | ($9.26B) | ($8.33B) | ($8.72B) | ($10.65B) | ($3.06B) |
| Dividends Paid | ($7.86B) | ($7.62B) | ($7.25B) | ($7.51B) | ($7.37B) |
| Debt Issued / Repaid | $2.72B | $4.39B | ($1.94B) | ($2.58B) | ($5.67B) |
| Net Cash from Financing | ($14.94B) | ($11.74B) | ($14.28B) | ($20.56B) | ($16.26B) |
| Free Cash Flow | |||||
| Free Cash Flow | $17.69B | $13.80B | $11.71B | $12.00B | $12.52B |
| FCF Margin %(computed) | 32.27% | 26.69% | 25.09% | 27.60% | 28.46% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Novartis AG
关于Novartis AG（NVS）现金流量表
Novartis AG 2025财年经营活动现金流$19.24B，自由现金流$17.69B（FCF利润率32.27%），资本支出($1.56B)。
常见问题
NVS · 4 问Novartis AG 2025财年自由现金流$17.69B，同比up28.1%。
NVS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08